Understanding causes of death among men with prostate cancer recurrence after localized treatment is essential for informed decision-making.

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

These changes are meant to limit the use of the shots while experts collect more data on how well they work for healthy people.

The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy.

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

Deleterious effect of lipoprotein(a) ≥180 nmol/L possibly mitigated by high-impact LDL-cholesterol-lowering therapy.